FDA approves Moderna’s mRNA flu vaccine after initial pushback
The U.S. Food and Drug Administration has approved a new seasonal flu vaccine from Moderna that uses mRNA technology, the drugmaker announced Wednesday.Called mFLUSIVA, it is approved for adults ages 50 and older. It’s the first influenza vaccine using mRNA technology to receive FDA approval.The approval “reflects the ongoing potential of our mRNA platform to help address … Read more